Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DDAH-1 modulator
- Development stage
- Preclinical
- Lead developer
- Vasculonics
- Modality
- Small Molecules
- Administration
- Inhalation, Intravenous, Intraperitoneal, Intraarterial, Intramuscular, Subcutaneous, Intramedullary, Intrathecal, Intraventricular, Oral, Intranasal, Transdermal, Topical, Local Injection
01
Overview
Vasculonics is developing a preclinical-stage small molecule modulator of Dimethylarginine Dimethylaminohydrolase 1 (DDAH-1) for the treatment of Acute Kidney Injury (AKI). DDAH-1 is the primary enzyme responsible for the metabolism of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS). Elevated levels of ADMA are associated with endothelial dysfunction and reduced nitric oxide bioavailability, which contribute to the pathogenesis of AKI. By modulating DDAH-1 activity, this therapeutic aims to lower ADMA levels, thereby restoring nitric oxide production and improving renal perfusion and function. The program has received SBIR Phase I funding and is currently in the lead optimization and preclinical testing phase.
- Other names
- DDAH-1 small molecule modulatorDDAH1 small molecule modulatorDDAH 1 small molecule modulatorVasculonics DDAH-1 program
02
Targets
DDAH (Dimethylarginine dimethylaminohydrolase 1)
Beyond the preview
Go deeper on DDAH-1 modulator.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DDAH-1 modulator.